Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

2019

Beca de Apoyo del Centro de Cancer NIH / NCI P30 CA008748. Kyowa Kirin (Princeton, NJ, EE. UU.).

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

0

References

0

Citations